Germ Cell Tumor
63
21
30
16
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.5%
6 terminated out of 63 trials
72.7%
-13.8% vs benchmark
6%
4 trials in Phase 3/4
19%
3 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (63)
A Study of ZW251 in Participants With Advanced Solid Tumors
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Tumor-Lymph Node Mapping
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
A Study of DS-9606a in Patients With Advanced Solid Tumors
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
A Study of miRNA 371 in Patients With Germ Cell Tumors
Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Germ Cell Tumor and Testicular Tumor DNA Registry
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
CD30 CAR for CD30+ NSGCT
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Maintenance Zanzalintinib With Etoposide After HDCT in GCT